Telenursing and Breast Cancer: The Turkish Case
Breast Cancer Female

About this trial
This is an interventional supportive care trial for Breast Cancer Female focused on measuring telenursing, breast cancer, chemotherapy, symptom management
Eligibility Criteria
Inclusion Criteria:
- is volunteering to participate in the research,
- is 18 years of age or over,
- can communicate in Turkish,
- has Turkish literacy skills,
- has no hearing, vision problems, and mental disability that may hinder communication,
- is female,
- has a diagnosis of breast cancer for the first time in her life and consequently receiving chemotherapy treatment in the same protocols for the first time,
- did not have a different diagnosis of cancer and related chemotherapy treatment.
Exclusion Criteria:
- Having been diagnosed with breast cancer before and received chemotherapy treatment accordingly,
- Having been diagnosed with different cancers before and had chemotherapy treatment related to it,
- Cancer treatment with oral medications,
- Refuse to participate in the study
- Refuse education/counseling
- Not knowing Turkish
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Intervention Group
No Intervention: Control Group
After the first treatment, every week the patients were called and consulted by telenursing. During the next there chemotherapy treatments, Edmonton Symptom Assessment System and General Comfort Questionnaire were filled. The study ended with the fourth cycle chemotherapy. A total of six telephone calls and 3 face-to-face follow-ups were done with each of the intervention group patients. Face-to-face follow-up with patients during chemotherapy treatments lasted for about 20-30 minutes, and patients were evaluated three times in terms of symptom severity and comfort level.
During their first treatment the "Patient Identification Form" was filled and they were trained, which is the routine practice of the clinic. Patients were informed about the "Symptom follow-up form", asked to mark the symptoms and signs they experienced due to the disease and treatment in the form between the two chemotherapy treatments and to note when they experienced and how they resolved this symptom. When the patients came to the second treatment, the first follow-up of the patients was done. The investigator filled Edmonton Symptom Assessment System and General Comfort Questionnaire forms via face-to-face interviews. The "Symptom Follow-up Form" given to the patients in the previous chemotherapy treatment was collected and the same new form was given. They were requested to bring this form in their next treatment. The same protocol was followed during the third and fourth chemotherapy treatment